Exebacase, a recombinantly produced lysin (cell wall hydrolase), and comparator antibiotics were tested by the broth microdilution method against strain sets of Staphylococcus and Streptococcus spp., which are the most common causes of infective endocarditis in humans. Exebacase was active against all Staphylococcus spp. tested, including S. aureus and coagulase-negative staphylococci (MIC50/90, 0.5/1 μg/ml). Activity against Streptococcus spp.
KEYWORDS: Staphylococcus, Streptococcus, antimicrobial activity, exebacase, infective endocarditis, lysin
ABSTRACT
Exebacase, a recombinantly produced lysin (cell wall hydrolase), and comparator antibiotics were tested by the broth microdilution method against strain sets of Staphylococcus and Streptococcus spp., which are the most common causes of infective endocarditis in humans. Exebacase was active against all Staphylococcus spp. tested, including S. aureus and coagulase-negative staphylococci (MIC50/90, 0.5/1 μg/ml). Activity against Streptococcus spp. was variable, with S. pyogenes, S. agalactiae, and S. dysgalactiae (MIC50/90, 1/2 μg/ml) among the most susceptible.
TEXT
Infective endocarditis (IE) is a life-threatening disease with a poor prognosis, reflected by hospital mortality rates of up to 20 to 40% despite the use of high-dose and long-term intravenous antibiotic therapy (1, 2). Surgical intervention is frequently required in many cases to eradicate the infection and preserve cardiac function (3).
A significant challenge in the treatment of IE concerns the ability of colonizing bacteria, primarily Staphylococcus and Streptococcus spp., to adhere to cardiac surfaces and form biofilm-like vegetations which can be refractory to antibiotics and immune surveillance, resulting in persistent and relapsing infections (4–6). Current IDSA guidelines recommend either vancomycin or daptomycin for the treatment of IE caused by methicillin-resistant Staphylococcus aureus (MRSA) in adults (3, 7); however, vancomycin has been associated with poor clinical outcomes (4, 8), and daptomycin, the most recent drug approved by the U.S. Food and Drug Administration (in 2006) for S. aureus bloodstream infections (9), exhibited a clinical cure rate of 44.2% in a phase 3 trial for S. aureus bacteremia and endocarditis (10). New and more effective antimicrobial agents are required to address the challenging characteristics of bacteria in biofilm, in particular high cell densities, low growth rates, “persister” subpopulations, and other protective mechanisms (3, 4, 11).
One promising approach, now under clinical development to target bacteria growing in a biofilm, is based on a new antimicrobial class of direct lytic agents (DLAs), which includes a large family of bacteriophage-encoded cell wall hydrolases called lysins (12–14). As recombinantly expressed and purified enzymes, lysins elicit rapid bactericidal effects on specific bacterial organisms. Exebacase (formerly CF-301) is a potent antistaphylococcal lysin, with distinguishing features that include a low propensity for resistance, synergy with conventional antibiotics, no antibiotic cross-resistance, an extended postantibiotic effect, and, significantly, potent activity against Gram-positive bacteria growing in biofilms (15–21). Exebacase is, furthermore, the first DLA to report results from a phase 2 (Ph2) clinical trial, which demonstrated 42.8% higher clinical responder rates with a single dose of exebacase used in addition to standard-of-care antibiotics (SOC) versus SOC alone for the treatment of MRSA bacteremia, including endocarditis (18, 22). Exebacase represents a novel approach to treating IE caused by S. aureus that leverages both the antibiofilm and bactericidal activities of exebacase and the potent activities of antibiotics against planktonic cells.
In the present study, the in vitro activity of exebacase and comparator antibiotics (i.e., daptomycin and vancomycin) were evaluated against a range of bacterial species most commonly associated with IE (Table 1). Staphylococcus aureus is the primary cause of IE, in addition to other common pathogens such as coagulase-negative staphylococci, enterococci, viridans group streptococci, and other streptococci. Whereas the potent activity of exebacase against S. aureus is well described, only limited data exist for the other staphylococcal and streptococcal pathogens (15, 16, 21). The purpose of this study was to provide a greater understanding of exebacase activity among the main staphylococcal and streptococcal pathogens associated with IE.
TABLE 1.
Organism | Microorganisms identified by blood culture (%) in various studiesa
|
||||||
---|---|---|---|---|---|---|---|
Yuan (39), n = 167 | Murdoch et al. (2), n = 2,781 | Farag et al. (40), n = 360 | Munoz et al. (41), n = 1,804 | Xu et al. (42), n = 105 | Selton-Suty et al. (43), n = 497 | Yombi et al. (44), n = 212 | |
S. aureus | 44.3 | 31.0 | 24.7 | 40.3 | 10.4 | 26.6 | 23.6 |
S. epidermidis | 1.8 | 6.4 | 6.1 | ||||
S. lugdunensis | 1.8 | 1.4 | 0.9 | ||||
Other CoNSb | 3.0 | 11.0 | 4.6 | 16.7* | 12.4* | 9.7* | 5.3 |
Streptococcus viridansc | 6.6 | 17.0 | 38.6 | 12.3 | 58.1 | 16.0 | |
S. agalactiae | 3.0 | 1.4 | 2.4 | ||||
S. pyogenes | 0.9 | ||||||
S. pneumoniae | 0.6 | ||||||
S. gallolyticus | 6 | 6.1 | 6.4 | 12.5 | 7.1 | ||
“Oral” streptococcid | 18.7 | ||||||
Streptococcus group G | 1.4 | ||||||
Enterococcus faecalis | 6.6 | 11.1 | 4.8 | 11.8 | |||
Enterococcus spp.e | 12.7 |
References for each study are indicated (n, number of patients in each study). A set of references were chosen based on a literature review of PubMed performed in 2018 focusing on the most common causes of IE that provided an overall prevalence of each pathogen that was encountered. The findings are consistent with the general understanding of pathogens associated with IE (3, 4, 38). *, studies that grouped all CoNS species together.
Some studies here distinguish S. epidermidis and S. lugdunensis from other more infrequent CoNS organisms associated with IE, including S. capitis, S. warneri, and S. haemolyticus (25, 40, 45).
The viridans group streptococci causing IE include S. mitis, S. sanguinis, S. mutans, S. salivarius, S. gordonii, S. intermedius, and S. anginosus (28, 46–48).
Viridans streptococci are referred to as oral streptococci in the indicated study.
Species not provided; however, E. faecalis causes ∼97% of IE cases associated with enterococci (3).
The strains and isolates used in this study were acquired from collections and repositories in the United States, Europe, and Asia and were confirmed at the species level by each source. The isolates were isolated from a range of infection types, including bacteremia (and endocarditis), skin and soft tissue infections, and respiratory infections (see Tables S1 and S2 in the supplemental material). A range of infections types were included to ensure a sufficient number of isolates for each target species.
The MICs of exebacase against staphylococci were determined by broth microdilution (BMD) (23) using a nonstandard antimicrobial susceptibility testing (AST) medium comprised of cation-adjusted Mueller-Hinton broth (CAMHB) supplemented with horse serum (Sigma-Aldrich) and dithiothreitol (Sigma-Aldrich) to final concentrations of 25% and 0.5 mM, respectively. This medium, referred to as CAMHB-HSD, was approved for use in exebacase AST by the Clinical and Laboratory Standards Institute (CLSI) AST Subcommittee, based on the acceptance of quality control (QC) ranges determined for the QC strains ATCC 29213 and ATCC 29212 in CLSI M23 studies using CAMHB-HSD (24). Additional supplementation with 2.5% lysed horse red blood cells (Remel; Thermo Fisher) was included for analyses of streptococcal isolates, as recommended by the CLSI (23). Daptomycin (Sigma-Aldrich) and vancomycin hydrochloride (Sigma-Aldrich) were analyzed in parallel (using the same inoculum), following the reference BMD method for each (23).
Exebacase activity was first confirmed using sets of 73 methicillin-susceptible S. aureus (MSSA) and 74 MRSA isolates, which demonstrated MIC50/90 values of 0.5/0.5 μg/ml and 0.5/1 μg/ml and ranges of 0.25 to 1 μg/ml and 0.5 to 2 μg/ml, respectively (Table 2). Similar levels activity were next observed for each coagulase-negative staphylococcal species, including Staphylococcus epidermidis (MIC50/90 = 0.5/0.5 μg/ml), Staphylococcus lugdunensis (MIC50/90 = 1/1 μg/ml), Staphylococcus haemolyticus (MIC50/90 = 0.5/1 μg/ml), Staphylococcus capitis (MIC50/90 = 1/2 μg/ml), and Staphylococcus warneri (MIC50/90 = 0.5/1 μg/ml). Staphylococcus hominis, only rarely associated with IE (25), was tested (n = 2 strains) and demonstrated exebacase MIC values of 0.125 and 0.25 μg/ml (data not shown). Other staphylococcal species tested included Staphylococcus pseudintermedius (MIC = 0.25 μg/ml, each of n = 6 isolates), S. sciuri (MIC = 2 μg/ml, n = 3 isolates), Staphylococcus simulans (MIC = 0.125 μg/ml, n = 1 isolate), and Staphylococcus hyicus (MIC = 0.25 μg/ml, n = 1 isolate). MICs for daptomycin and vancomycin were observed with ranges of 0.125 to 2 μg/ml and 0.5 to 4 μg/ml, respectively, for all staphylococci tested, consistent with expected ranges (26, 27).
TABLE 2.
Organism | n | Exebacase |
DAP |
VAN |
||||||
---|---|---|---|---|---|---|---|---|---|---|
MIC50a | MIC90 | Range | MIC50 | MIC90 | Range | MIC50 | MIC90 | Range | ||
S. aureus (MSSA) | 73 | 0.5 | 0.5 | 0.25–1 | 0.25 | 0.25 | 0.125–0.5 | 1 | 1 | 0.5–1 |
S. aureus (MRSA) | 74 | 0.5 | 1 | 0.5–2 | 0.25 | 0.5 | 0.125–1 | 1 | 1 | 1–2 |
S. epidermidisb | 52 | 0.5 | 0.5 | 0.125–2 | ND | ND | ND | ND | ND | ND |
S. lugdunensis | 46 | 1 | 1 | 0.25–2 | 0.5 | 1 | 0.25–2 | 1 | 1 | 0.5–2 |
S. haemolyticus | 34 | 0.5 | 1 | 0.25–2 | 0.5 | 1 | 0.25–2 | 1 | 2 | 0.5–4 |
S. capitis | 13 | 1 | 2 | 0.25–4 | 0.5 | 1 | 0.25–1 | 1 | 1 | 0.5–2 |
S. warneri | 21 | 0.5 | 1 | 0.06–1 | 0.5 | 2 | 0.25–2 | 1 | 2 | 0.25–2 |
MIC values are indicated in μg/ml. DAP, daptomycin; VAN, vancomycin.
MIC values for DAP and VAN data were not determined (ND) for S. epidermidis.
The majority of viridans streptococci tested, in addition to Streptococcus pneumoniae and Enterococcus faecalis (formerly group D streptococcus), exhibited high MICs for exebacase, with values ranging up to >512 μg/ml (Table 3). Notable exceptions included Streptococcus intermedius, Streptococcus pyogenes (Lancefield group A), Streptococcus agalactiae (Lancefield group B), and Streptococcus dysgalactiae (Lancefield group G), with MIC ranges of 0.06 to 0.5, 0.5 to 4, 0.25 to 4, and 1 to 2 μg/ml, respectively. Unlike many of the viridans streptococci and E. faecalis which primarily cause subacute IE, S. intermedius (a viridans group species) and both S. agalactiae and S. dysgalactiae are, interestingly, associated with the more aggressive acute disease caused by staphylococci and resulting in rapid destruction of the endocardium (28–32).
TABLE 3.
Organism | Streptococcus group | n | Exebacase |
DAP |
VAN |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
MIC50a | MIC90 | Range | MIC50 | MIC90 | Range | MIC50 | MIC90 | Range | |||
S. anginosus | Viridans | 10 | 32 | 64 | 1–64 | 0.5 | 0.5 | 0.25–0.5 | 0.5 | 1 | 0.5–1 |
S. gordonii | Viridans | 11 | 4 | 8 | 0.5–8 | 0.5 | 0.5 | 0.25–1 | 0.5 | 1 | 0.5–1 |
S. mitis | Viridans | 17 | 2 | 8 | 0.5–64 | 0.5 | 1 | 0.125–1 | 0.5 | 0.5 | 0.25–0.5 |
S. mutans | Viridans | 22 | 32 | 64 | 1–>64 | 0.5 | 1 | 0.25–8 | 1 | 1 | 0.25–1 |
S. oralis | Viridans | 15 | 4 | 64 | 0.5–64 | 0.5 | 0.5 | 0.25–1 | 0.5 | 1 | 0.5–1 |
S. salivarius | Viridans | 12 | 2 | 8 | 0.5–8 | 0.25 | 0.5 | 0.06–0.5 | 0.5 | 0.5 | 0.25–0.5 |
S. sanguinis | Viridans | 15 | 4 | 16 | 2–32 | 0.25 | 1 | 0.06–1 | 0.5 | 0.5 | 0.5–2 |
S. intermediusb | Viridans | 10 | 0.25 | 0.5 | 0.06–0.5 | ND | ND | ND | ND | ND | ND |
S. gallolyticus | Bovis | 19 | 64 | >512 | 0.25–>512 | 0.125 | 0.25 | 0.06–0.5 | 0.25 | 0.5 | 0.25–0.5 |
S. pyogenes | A | 100 | 1 | 2 | 0.5–4 | 0.03 | 0.06 | 0.016–0.06 | 0.5 | 0.5 | 0.25–0.5 |
S. agalactiae | B | 97 | 1 | 2 | 0.25–4 | 0.125 | 0.25 | 0.125–0.25 | 0.5 | 0.5 | 0.25–0.5 |
S. dysgalactiae | G | 22 | 1 | 2 | 1–2 | 0.125 | 0.25 | 0.06–0.5 | 0.5 | 0.5 | 0.25–1 |
S. pneumoniae | 59 | 4 | 32 | 1–64 | 0.125 | 0.5 | 0.06–0.25 | 0.25 | 0.5 | 0.25–0.5 | |
E. faecalis | D (formerly) | 18 | 16 | 64 | 1–256 | 0.5 | 0.5 | 0.25–0.5 | 1 | 2 | 0.5–2 |
MIC values are indicated in μg/ml. DAP, daptomycin; VAN, vancomycin.
MIC values for DAP and VAN data were not determined (ND) for S. intermedius.
Overall, the exebacase data presented here demonstrated promising in vitro antimicrobial activity, with MIC values of ≤2 μg/ml against all staphylococcal and a subset of streptococcal species. Importantly, data from exposure target attainment animal studies, pharmacokinetic/pharmacodynamic modeling, and preliminary nonclinical breakpoint assessments indicate that strains with MIC values of ≤2 μg/ml are expected to be susceptible to the clinical dose of exebacase (0.25 mg/kg) studied in Ph2 (33–35). Our findings are particularly significant considering that staphylococci and streptococci are the most frequently isolated Gram-positive cocci isolated in native and prosthetic valve infections (3, 4, 36–38).
The concept of combining the potent antibiofilm and bactericidal activities of lysins with the well-understood strengths of antibiotics represents a completely novel approach that is under investigation in a Ph2 clinical trial for the treatment of S. aureus bacteremia and endocarditis with exebacase in addition to conventional antibiotics. The trial is expected to provide a proof of concept for the novel treatment approach.
Supplementary Material
ACKNOWLEDGMENTS
This study was supported by funds from ContraFect Corporation and CDMRP award W81XWH-16-1-0245.
We thank Valerie Albrecht and Bernard Beall (CDC), James Swezey (USDA), Vincent Fischetti and Mary Windels (The Rockefeller University), Lars Westblade, Amy Robertson, and Stephen Jenkins (New York Presbyterian/Weill Cornell Medical Center), Elisabeth Inganäs (CCUG), Hanna Hintze (DSMZ), Els Vercoutere (Leibniz Institut, BCCM/LMG), and Kazuhiko Nakano (Osaka University) for kind help with acquiring strains. We thank Temima Yellin for assistance in MIC testing.
Footnotes
Supplemental material for this article may be found at https://doi.org/10.1128/AAC.01078-19.
REFERENCES
- 1.Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, D’Aiello I, Picchi A, De Sensi F, Habib G. 2017. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovasc Diagn Ther 7:27–35. doi: 10.21037/cdt.2016.08.09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falco V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH, International Collaboration on Endocarditis-Prospective Cohort Study Investigators. 2009. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169:463–473. doi: 10.1001/archinternmed.2008.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA. 2015. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 132:1435–1486. doi: 10.1161/CIR.0000000000000296. [DOI] [PubMed] [Google Scholar]
- 4.Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG Jr. 2016. Infective endocarditis. Nat Rev Dis Primers 2:16059. doi: 10.1038/nrdp.2016.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Elgharably H, Hussain ST, Shrestha NK, Blackstone EH, Pettersson GB. 2016. Current hypotheses in cardiac surgery: biofilm in infective endocarditis. Semin Thorac Cardiovasc Surg 28:56–59. doi: 10.1053/j.semtcvs.2015.12.005. [DOI] [PubMed] [Google Scholar]
- 6.Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E. 2018. Strategies against methicillin-resistant Staphylococcus aureus persisters. Future Med Chem 10:779–794. doi: 10.4155/fmc-2017-0199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–55. doi: 10.1093/cid/ciq146. [DOI] [PubMed] [Google Scholar]
- 8.McConeghy KW, Bleasdale SC, Rodvold KA. 2013. The empirical combination of vancomycin and a beta-lactam for staphylococcal bacteremia. Clin Infect Dis 57:1760–1765. doi: 10.1093/cid/cit560. [DOI] [PubMed] [Google Scholar]
- 9.Bamberger DM. 2007. Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin. Ther Clin Risk Manag 3:675–684. [PMC free article] [PubMed] [Google Scholar]
- 10.Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665. doi: 10.1056/NEJMoa053783. [DOI] [PubMed] [Google Scholar]
- 11.Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, Schafers HJ, Prendergast BD. 2017. Challenges in infective endocarditis. J Am Coll Cardiol 69:325–344. doi: 10.1016/j.jacc.2016.10.066. [DOI] [PubMed] [Google Scholar]
- 12.Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, Donovan DM. 2012. Endolysins as antimicrobials. Adv Virus Res 83:299–365. doi: 10.1016/B978-0-12-394438-2.00007-4. [DOI] [PubMed] [Google Scholar]
- 13.Wittekind M, Schuch R. 2016. Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments. Curr Opin Microbiol 33:18–24. doi: 10.1016/j.mib.2016.05.006. [DOI] [PubMed] [Google Scholar]
- 14.Fischetti VA, Nelson D, Schuch R. 2006. Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 24:1508–1511. doi: 10.1038/nbt1206-1508. [DOI] [PubMed] [Google Scholar]
- 15.Schuch R, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, Fischetti VA, Huang DB, Nowinski RC, Wittekind M. 2014. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis 209:1469–1478. doi: 10.1093/infdis/jit637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Indiani C, Sauve K, Raz A, Abdelhady W, Xiong YQ, Cassino C, Bayer AS, Schuch R. 2019. The anti-staphylococcal lysin, CF-301, activates key host factors in human blood to potentiate MRSA bacteriolysis. Antimicrob Agents Chemother 63:e02291-18. doi: 10.1128/AAC.02291-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Oh JT, Cassino C, Schuch R. 2019. Postantibiotic and sub-MIC effects of exebacase (lysin CF-301) enhance antimicrobial activity against Staphylococcus aureus. Antimicrob Agents Chemother 63:e02616-18. doi: 10.1128/AAC.02616-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fowler VG, Das A, Lipka J, Schuch R, Cassino C. 2019. Exebacase (lysin CF-301) improved clinical responder rates in methicillin-resistant Staphylococcus aureus bacteremia and endocarditis compared to standard of care antibiotics alone in a first-in-patient phase 2 study, abstr L0012 European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands. [Google Scholar]
- 19.Oh J, Abdelhady W, Xiong YQ, Jones S, Cassino C, Bayer AS, Schuch R. 2018. Lysin CF-301 administered in addition to vancomycin (VAN) suppresses the emergence of reduced susceptibilities to VAN within cardiac vegetations in a rabbit model of MRSA infective endocarditis (IE), abstr Sunday-535 ASM Microbe, Atlanta, GA. [Google Scholar]
- 20.Oh J, Schuch R. 2017. Low propensity of resistance development in vitro in Staphylococcus aureus with lysin CF-301, abstr Friday-330 ASM Microbe, New Orleans, LA. [Google Scholar]
- 21.Schuch R, Khan BK, Raz A, Rotolo JA, Wittekind M. 2017. Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent. Antimicrob Agents Chemother 61:e02666-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.ClinicalTrials.gov. 2017. Safety, efficacy, and pharmacokinetics of CF-301 versus placebo in addition to antibacterial therapy for treatment of S. aureus bacteremia. https://clinicaltrials.gov/ct2/show/NCT03163446.
- 23.CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 10th ed Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
- 24.Traczewski MM, Oh J, Schuch R. 2017. Quality control studies of CF-301 versus Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212, abstr Friday-961 ASM Microbe, New Orleans, LA. [Google Scholar]
- 25.Petti CA, Simmon KE, Miro JM, Hoen B, Marco F, Chu VH, Athan E, Bukovski S, Bouza E, Bradley S, Fowler VG, Giannitsioti E, Gordon D, Reinbott P, Korman T, Lang S, Garcia-de-la-Maria C, Raglio A, Morris AJ, Plesiat P, Ryan S, Doco-Lecompte T, Tripodi F, Utili R, Wray D, Federspiel JJ, Boisson K, Reller LB, Murdoch DR, Woods CW, International Collaboration On Endocarditis-Microbiology Investigators. 2008. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J Clin Microbiol 46:1780–1784. doi: 10.1128/JCM.02405-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Sader HS, Mendes RE, Pfaller MA, Flamm RK. 2019. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. J Antimicrob Chemother doi: 10.1093/jac/dkz006. [DOI] [PubMed] [Google Scholar]
- 27.Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. 2018. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). Int J Antimicrob Agents 51:608–611. doi: 10.1016/j.ijantimicag.2017.12.011. [DOI] [PubMed] [Google Scholar]
- 28.Cunha BA, D’Elia AA, Pawar N, Schoch P. 2010. Viridans streptococcal (Streptococcus intermedius) mitral valve subacute bacterial endocarditis (SBE) in a patient with mitral valve prolapse after a dental procedure: the importance of antibiotic prophylaxis. Heart Lung 39:64–72. doi: 10.1016/j.hrtlng.2009.01.004. [DOI] [PubMed] [Google Scholar]
- 29.McDonald JR. 2009. Acute infective endocarditis. Infect Dis Clin North Am 23:643–664. doi: 10.1016/j.idc.2009.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Abdelghany M, Schenfeld L. 2014. Group B streptococcal infective endocarditis. J Infect Public Health 7:237–239. doi: 10.1016/j.jiph.2014.01.006. [DOI] [PubMed] [Google Scholar]
- 31.Lother SA, Jassal DS, Lagace-Wiens P, Keynan Y. 2017. Emerging group C and group G streptococcal endocarditis: a Canadian perspective. Int J Infect Dis 65:128–132. doi: 10.1016/j.ijid.2017.10.018. [DOI] [PubMed] [Google Scholar]
- 32.Dahl A, Bruun NE. 2013. Enterococcus faecalis infective endocarditis: focus on clinical aspects. Expert Rev Cardiovasc Ther 11:1247–1257. doi: 10.1586/14779072.2013.832482. [DOI] [PubMed] [Google Scholar]
- 33.Cassino C, Murphy G, Boyle J, Rotolo J, Wittekind M. 2016. Results of the first in human study of lysin CF-301 evaluating the safety, tolerability and pharmacokinetic profile in healthy volunteers, abstr EVLB62 ECCMID, Amsterdam, Netherlands. [Google Scholar]
- 34.Ghahramani P, Khariton T, Schuch R, Rotolo JA, Ramirez RA, Wittekind M. 2016. Pharmacokinetic indices driving antibacterial efficacy of CF-301: a novel first-in-class lysin, abstr W-59 American Conference on Pharmacometrics, Bellevue, WA. [Google Scholar]
- 35.Rotolo J, Ramirez RA, R S, Machacek M, Khariton T, Ghahramani P, Wittekind M. 2016. PK-PD driver of efficacy for CF-301, a novel anti-staphylococcal lysin: implications for human target dose, abstr LB-053 ASM Microbe, Boston, MA. [Google Scholar]
- 36.Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, Doco-Lecompte T, Celard M, Poyart C, Strady C, Chirouze C, Bes M, Cambau E, Iung B, Selton-Suty C, Hoen B, Group AS. 2012. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 59:1968–1976. doi: 10.1016/j.jacc.2012.02.029. [DOI] [PubMed] [Google Scholar]
- 37.Benito N, Miro JM, de LE, Cabell CH, del Rio A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr, ICE-PES Investigators. 2009. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med 150:586–594. doi: 10.7326/0003-4819-150-9-200905050-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Yang E, Frazee BW. 2018. Infective endocarditis. Emerg Med Clin North Am 36:645–663. doi: 10.1016/j.emc.2018.06.002. [DOI] [PubMed] [Google Scholar]
- 39.Yuan SM. 2014. Right-sided infective endocarditis: recent epidemiologic changes. Int J Clin Exp Med 7:199–218. [PMC free article] [PubMed] [Google Scholar]
- 40.Farag M, Borst T, Sabashnikov A, Zeriouh M, Schmack B, Arif R, Beller CJ, Popov AF, Kallenbach K, Ruhparwar A, Dohmen PM, Szabo G, Karck M, Weymann A. 2017. Surgery for infective endocarditis: outcomes and predictors of mortality in 360 consecutive patients. Med Sci Monit 23:3617–3626. doi: 10.12659/msm.902340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Munoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodriguez-Abella H, Farinas MC, Cobo Belaustegui M, Mestres C, Llinares P, Goenaga M, Navas E, Oteo JA, Tarabini P, Bouza E, Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España. 2015. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Medicine 94:e1816. doi: 10.1097/MD.0000000000001816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Xu H, Cai S, Dai H. 2016. Characteristics of infective endocarditis in a tertiary hospital in East China. PLoS One 11:e0166764. doi: 10.1371/journal.pone.0166764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Selton-Suty C, Celard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B, Group AS. 2012. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 54:1230–1239. doi: 10.1093/cid/cis199. [DOI] [PubMed] [Google Scholar]
- 44.Yombi JC, Yuma SN, Pasquet A, Astarci P, Robert A, Rodriguez HV. 2017. Staphylococcal versus streptococcal infective endocarditis in a tertiary hospital in Belgium: epidemiology, clinical characteristics and outcome. Acta Clin Belgium 72:417–423. doi: 10.1080/17843286.2017.1309341. [DOI] [PubMed] [Google Scholar]
- 45.Kuvhenguhwa MS, Belgrave KO, Shah SU, Bayer AS, Miller LG. 2017. A case of early prosthetic valve endocarditis caused by Staphylococcus warneri in a patient presenting with congestive heart failure. Cardiol Res 8:236–240. doi: 10.14740/cr588w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Kim SL, Gordon SM, Shrestha NK. 2018. Distribution of streptococcal groups causing infective endocarditis: a descriptive study. Diagn Microbiol Infect Dis 91:269–272. doi: 10.1016/j.diagmicrobio.2018.02.015. [DOI] [PubMed] [Google Scholar]
- 47.Naveen Kumar V, van der Linden M, Menon T, Nitsche-Schmitz DP. 2014. Viridans and bovis group streptococci that cause infective endocarditis in two regions with contrasting epidemiology. Int J Med Microbiol 304:262–268. doi: 10.1016/j.ijmm.2013.10.004. [DOI] [PubMed] [Google Scholar]
- 48.Dadon Z, Cohen A, Szterenlicht YM, Assous MV, Barzilay Y, Raveh-Brawer D, Yinnon AM, Munter G. 2017. Spondylodiskitis and endocarditis due to Streptococcus gordonii. Ann Clin Microbiol Antimicrob 16:68. doi: 10.1186/s12941-017-0243-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.